A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma

Inclusion Criteria: * Confirmation of cancer by biopsy (tissue sample) * Phase 1: patients with advanced or metastatic disease that have failed conventional therapy * Phase 2: patients with previously untreated NSCLC, excluding squamous cell histology and cavitating lesions * Age ≥18 years * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Adequate renal, liver and bone marrow function. * Negative pregnancy test (serum or urine) in females of childbearing potential within 7 days of the initial dose of aflibercept * Ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures * Institutional Review Board (IRB) approved, signed and dated informed consent form Exclusion Criteria: * Prior treatment with study medications * Untreated, symptomatic, or progressive Central Nervous System cancer and/or spinal cord compression. Patients with treated brain metastases must have been without symptoms for at least 3 months * Surgery up to 4 weeks prior to the initial administration of aflibercept and/or incomplete wound healing * Anti-VEGF therapy up to 4 weeks prior to the initial administration of aflibercept (for phase 1 only) * Chemotherapy up to 4 weeks prior to the initial administration of aflibercept (for phase 1 only) * Other investigational treatment up to 4 weeks prior to the initial administration of aflibercept * Any of the following up to 6 months (24 weeks) prior to the initial administration of aflibercept: * Severe cardiovascular disease or event * Cerebrovascular accident, transient ischemic attack, or moderate to severe peripheral neuropathy * Erosive esophagitis or gastritis, infectious or inflammatory bowel disease, and diverticulitis * Deep vein thrombosis, pulmonary embolism, or other clotting event * Episode(s)of moderate to severe, continuous bleeding * Breast-feeding or pregnancy